Xingge Xu

Mr. Xingge Xu

McGill University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
OFOmar Farnos
Omar Farnos
AVAlina Venereo-Sánchez
Alina Venereo-Sánchez
XXXingge Xu
Xingge Xu
CCCindy Chan
Cindy Chan
SDShantoshini Dash
Shantoshini Dash
Amine KamenAmine Kamen
Amine Kamen
Vaccine design strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the Spike protein or its subunits as the main antigen target of neutralizing antibodies. In this work, we propose rapid production methods of an extended segment of the Spike Receptor Binding Domain (RBD) in HEK293SF cells cultured in suspension, in serum-free media, as a major component of a COVID-19 subunit vaccine under development. The expression of RBD, engineered with a sortase-recognition motif for protein-based carrier coupling, was achieved at high yields by plasmid transient transfection or human type-5-adenoviral infection of the cells, in a period of only two and three weeks, respectively. Both production methods were evaluated in 3L-controlled bioreactors with upstream and downstream bioprocess improvements, resulting in a product recovery with over 95% purity. Adenoviral infection led to over 100 µg/mL of RBD in culture supernatants, which was around 7-fold higher than levels obtained in transfected cultures. The monosaccharide and sialic acid content was similar in the RBD protein from the two production approaches. It also exhibited a proper conformational structure as recognized by monoclonal antibodies directed against key native Spike epitopes. Efficient direct binding to ACE2 was also demonstrated at similar levels in RBD obtained from both methods and from different production lots. Overall, we provide bioprocess-related data for the rapid, scalable manufacturing of low cost RBD based vaccines against SARS-CoV-2, with the added value of making a functional antigen available to support further research on uncovering mechanisms of virus binding and entry as well as screening for potential COVID-19 therapeutics.

13 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ZYZeyu Yang
Zeyu Yang
XXXingge Xu
Xingge Xu
CSCristina AT Silva
Cristina AT Silva
OFOmar Farnos
Omar Farnos
AVAlina Venereo-Sanchez
Alina Venereo-Sanchez
Amine KamenAmine Kamen
Amine Kamen
New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread of the disease and reduce its severity, the development of robust bioprocesses for producing pandemic influenza vaccines is exceptionally important. Herein, a membrane chromatography-based downstream processing platform with a demonstrated industrial application potential was established. Cell culture-derived influenza virus H1N1/A/PR/8/34 was harvested from benchtop bioreactor cultures. For the clarification of the cell culture broth, a depth filtration was selected as an alternative to centrifugation. After inactivation, an anion exchange chromatography membrane was used for viral capture and further processing. Additionally, two pandemic influenza virus strains, the H7N9 subtype of the A/Anhui/1/2013 and H3N2/A/Hong Kong/8/64, were successfully processed through similar downstream process steps establishing optimized process parameters. Overall, 41.3–62.5% viral recovery was achieved, with the removal of 86.3–96.5% host cell DNA and 95.5–99.7% of proteins. The proposed membrane chromatography purification is a scalable and generic method for the processing of different influenza strains and is a promising alternative to the current industrial purification of influenza vaccines based on ultracentrifugation methodologies.

25 October 2022 in Processes
Verified
Journal Article
Open access
PDF file
Cristovão Freitas Iglesias JrCristovão Freitas Iglesias Jr
Cristovão Freitas Iglesias Jr
XXXingge Xu
Xingge Xu
VMVarun Mehta
Varun Mehta
MAMounia Akassou
Mounia Akassou
AVAlina Venereo-Sanchez
Alina Venereo-Sanchez
MBMiodrag Bolic
Miodrag Bolic
The recombinant adeno-associated virus (rAAV) is a viral vector technology for gene therapy that is considered the safest and most effective way to repair single-gene abnormalities in non-dividing cells. However, improving the viral titer productivity in rAAV production remains challenging. The first step to this end is to effectively monitor the process state variables (cell density, GLC, GLN, LAC, AMM, and rAAV viral titer) to improve the control performance for an enhanced productivity. However, the current approaches to monitoring are expensive, laborious, and time-consuming. This paper presents an extended Kalman filter (EKF) approach used to monitor the rAAV production using the online viable cell density measurements and estimating the other state variables measured at a low frequency. The proposed EKF uses an unstructured mechanistic kinetic model applicable in the upstream process. Three datasets were used for parameter estimation, calibration, and testing, and the data were collected from the production of rAAV through a triple-plasmid transfection of HEK293SF-3F6 cells. Overall, the proposed approach accurately estimated metabolite concentrations and the rAAV production yield. Therefore, the approach has a high potential to be extended to an online soft sensor and to be classified as a cost-effective and fast approach to the monitoring of rAAV production.